Latest news
Replimune (REPL) Gains FDA Accelerated Approval for Tudriqev in Advanced Melanoma - GuruFocusGuruFocus · Fri, 07 Aug 2026 00:45:22 GMTS&P 500, Dow, Nasdaq End Lower Amid Hormuz Uncertainty As Investors Await Jobs Data To Judge Fed Rate Course — SOUN, GOOGL, SPCX, NVDA In Focus - StocktwitsStocktwits · Thu, 06 Aug 2026 21:04:00 GMTOculis Q2 2026 Results: Finance Gains Narrow the Net Loss Despite Higher Costs - TradingKeyTradingKey · Thu, 06 Aug 2026 21:01:43 GMTTSLA-SPCX’s $16.8B Terafab Nears Construction As Elon Musk Details Compute Split — ‘25% For Tesla Optimus And ~75% For AI Spacecraft’ - StocktwitsStocktwits · Thu, 06 Aug 2026 19:31:00 GMTMRNA Stock Pares Gains Despite FDA Green Light For First mRNA Flu Vaccine — But Retail Cheers Pivot Beyond COVID - TradingViewTradingView · Thu, 06 Aug 2026 17:20:04 GMTARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule - StocktwitsStocktwits · Tue, 04 Aug 2026 02:29:33 GMTWeekly Recap: ANDA for generic Advair Diskus and Q1 profit down 34% - TradingViewTradingView · Mon, 03 Aug 2026 01:14:00 GMTReplimune (NASDAQ:REPL) Shares Surge, Gaining Nearly $600 Million in Equity Value Following FDA Decision - TechStock²TechStock² · Fri, 31 Jul 2026 14:01:51 GMT